ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This is Phase 2, multinational, randomized, blinded study to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics and pharmacodynamics of ALPN-101 (acazicolcept) in adults with moderate to severe active systemic lupus erythematosus (SLE)
Epistemonikos ID: 60bfc0eba82c9f49de8a9c8a9e42a5ecabcac932
First added on: May 08, 2024